SELECT trial

The SELECT trial demonstrates semaglutide's 20% reduction in major cardiovascular events in adults with obesity and cardiovascular disease. Mediation analysis reveals partial but uncertain roles of weight, inflammation, and glycemic markers, highlighting the need for further mechanistic research.